These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30589626)

  • 1. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
    Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
    J Manag Care Spec Pharm; 2018 Jan; 24(1):29-38. PubMed ID: 29290170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks.
    Agboola F; Lubinga S; Carlson J; Lin GA; Dreitlein WB; Pearson SD
    J Manag Care Spec Pharm; 2019 Feb; 25(2):143-148. PubMed ID: 30698087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.
    Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):712-713. PubMed ID: 29952702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness and Value of Treatments for Spinal Muscular Atrophy.
    Pearson SD; Thokala P; Stevenson M; Rind D
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1300-1306. PubMed ID: 31778620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma.
    Tice JA; Campbell JD; Synnott PG; Walsh JME; Kumar VM; Whittington M; Adair E; Rind D; Pearson SD
    J Manag Care Spec Pharm; 2019 May; 25(5):510-514. PubMed ID: 31039065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
    Otuonye IS; Banken R; Kumar VM; Pearson SD
    J Manag Care Spec Pharm; 2019 Jun; 25(6):630-634. PubMed ID: 31134864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and value of aducanumab for Alzheimer's disease.
    Synnott PG; Whittington MD; Lin GA; Rind DM; Pearson SD
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1613-1617. PubMed ID: 34714106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.